Price$1.32+0.08 (+6.88%)
01:30 PM07:45 PM
News · 26 weeks70+33%
2025-12-142026-06-07
Mix5090d
- Insider27(54%)
- SEC Filings11(22%)
- Other7(14%)
- Leadership2(4%)
- Offering2(4%)
- Earnings1(2%)
Latest news
25 items- PRNeuronetics Appoints Robert Greene as Senior Vice President SalesMALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Robert Greene has been appointed as the company's Senior Vice President Sales, effective June 1, 2026. Rob brings extensive experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service. Inducement Grant under Nasdaq Listing Rule 5635(c)(4) In connection with his hiring on June 1, 2026, the Co
- SECSEC Form SD filed by Neuronetics Inc.SD - Neuronetics, Inc. (0001227636) (Filer)
- INSIDERDirector Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 21% to 170,890 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERDirector Muir Glenn P was granted 30,000 shares, increasing direct ownership by 8% to 401,816 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERDirector Cucuz Sasha was granted 30,000 shares, increasing direct ownership by 2% to 1,542,798 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERDirector Conley Sheryl L was granted 30,000 shares, increasing direct ownership by 14% to 251,716 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERDirector Cascella Robert was granted 36,250 shares, increasing direct ownership by 6% to 625,017 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERDirector Amin Avinash was granted 30,000 shares, increasing direct ownership by 71% to 72,500 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- SECSEC Form 8-K filed by Neuronetics Inc.8-K - Neuronetics, Inc. (0001227636) (Filer)
- SECSEC Form 8-K filed by Neuronetics Inc.8-K - Neuronetics, Inc. (0001227636) (Filer)
- INSIDERAmendment: Former EVP, CFO and Treasurer Pfanstiel Steven sold $11,482 worth of shares (8,569 units at $1.34), decreasing direct ownership by 1% to 836,643 units (SEC Form 4) to satisfy withholding tax4/A - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERLarge owner Chernett Jorey bought $117,000 worth of shares (100,000 units at $1.17), increasing direct ownership by 0.96% to 10,553,988 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- PRNeuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS TreatmentMALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced a strategic partnership with ANT Neuro, a global leader in precision brain mapping and neuronavigation technologies, to expand the capabilities of the NeuroStar® Advanced Therapy System with advanced image-guided navigation technology. Through this preferred partnership, Neuronetics will offer ANT Neuro's visor2™ neuronavigation system alongside NeuroStar TMS, enabling healthcare p
- INSIDERNew insider Brown Francis X Iii claimed ownership of 19,968 shares (SEC Form 3)3 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERLarge owner Chernett Jorey bought $636,500 worth of shares (475,000 units at $1.34), increasing direct ownership by 5% to 10,453,988 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- SECSEC Form 10-Q filed by Neuronetics Inc.10-Q - Neuronetics, Inc. (0001227636) (Filer)
- SECNeuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure8-K - Neuronetics, Inc. (0001227636) (Filer)
- PRNeuronetics Reports First Quarter 2026 Financial and Operating ResultsMALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2026. First Quarter 2026 Highlights First quarter 2026 revenue of $34.5 million, up 8% compared to the first quarter 2025U.S. clinic revenue of $21.5 million, up 15% compared to the first quarter 2025Shipped 34 NeuroStar systems in the US; a 10% increase compared to
- PRNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date,
- INSIDERSEC Form 4 filed by Chernett Jorey4 - Neuronetics, Inc. (0001227636) (Issuer)
- PRNeuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference CallMALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that it plans to release first quarter 2026 financial and operating results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/3pztkve5. To listen to the conf
- PROptum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse PractitionersMALVERN, Pa., April 13, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, announced that Optum/United Healthcare/United Behavioral Health (Optum/UHC/UBH) has updated its Transcranial Magnetic Stimulation (TMS) clinical policy to allow psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer TMS therapy. Previously, this authority was limited to psychiatrists. The updated policy applies to PMHNPs operating in states where full practice a
- SECSEC Form EFFECT filed by Neuronetics Inc.EFFECT - Neuronetics, Inc. (0001227636) (Filer)
- SECSEC Form DEFA14A filed by Neuronetics Inc.DEFA14A - Neuronetics, Inc. (0001227636) (Filer)
- SECSEC Form DEF 14A filed by Neuronetics Inc.DEF 14A - Neuronetics, Inc. (0001227636) (Filer)
STIM FAQ
7 questionsWhat does Neuronetics Inc. do?
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company...Where does STIM stock trade?
Neuronetics Inc. (STIM) is listed on NASDAQ.What sector and industry is STIM in?
Neuronetics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Neuronetics Inc. go public?
Neuronetics Inc. (STIM) completed its IPO in 2018.What are analysts saying about STIM?
Neuronetics Inc. has had 4 recent analyst actions on file. The most recent action was from William Blair: Mkt Perform on 2024-08-13. Recent price targets cluster around $1200.00.What companies are similar to STIM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare STIM side-by-side with any of them on Quantisnow.How can I track STIM on Quantisnow?
Quantisnow aggregates Neuronetics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STIM to receive live email and push alerts on every new disclosure.